Category Archives: Biotechnology

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel07.07.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

Change in the Management Board of BRAIN AG

Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect

Zwingenberg, Germany07 July 2020

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Business Officer Ludger Roedder will leave the executive board by mutual agreement with immediate effect on July 7th, 2020 due to different strategic visions. Mr. Roedder will leave the BRAIN AG at the end of the calendar year.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, states: "We like to thank Ludger Roedder for his contribution and commitment to the development of the BRAIN AG since 2018 and wish him the most success for his next ventures. We feel very comfortable with the future setup of a two person's board consisting of Adriaan Moelker, CEO, and Lukas Linnig, CFO. Currently we are not planning a succession for Ludger Roedder".

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at http://www.brain-biotech.com.

B.R.A.I.NBiotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersHead of Investor RelationsPhone: +49-6251-9331-86E-Mail IR: mis@brain-biotech.com

Media ContactDr. Stephanie KonleManaging AssociateCorporate CommunicationsPhone +49-6251-9331-70Email: stk@brain-biotech.com

DisclaimerThis press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

07.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Excerpt from:
B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAI - PharmiWeb.com

Nektar Therapeutics (NKTR) is near the bottom in its industry group according to InvestorsObserver. NKTR gets an overall rating of 32. That means it scores higher than 32 percent of stocks. Nektar Therapeutics gets a 15 rank in the Biotechnology industry. Biotechnology is number 11 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 32 would rank higher than 32 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Nektar Therapeutics (NKTR) stock is trading at $24.83 as of 3:27 PM on Wednesday, Jul 8, a rise of $0.69, or 2.84% from the previous closing price of $24.14. The stock has traded between $23.86 and $24.88 so far today. Volume today is less active than usual. So far 561,924 shares have traded compared to average volume of 1,185,195 shares.

To see InvestorsObserver's Sentiment Score for Nektar Therapeutics click here.

See the original post:
Should You Buy Nektar Therapeutics (NKTR) in Biotechnology Industry? - InvestorsObserver

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Nanoparticles in Biotechnology and Pharmaceuticals Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Nanoparticles in Biotechnology and Pharmaceuticals market.

The research study includes the latest updates about the COVID-19 impact on the Nanoparticles in Biotechnology and Pharmaceuticals sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Nanoparticles in Biotechnology and Pharmaceuticals manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Nanoparticles in Biotechnology and Pharmaceuticals market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Nanoparticles in Biotechnology and Pharmaceuticals sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Nanoparticles in Biotechnology and Pharmaceuticals, the report covers-

Bytype1

In Market Segmentation by Applications of the Nanoparticles in Biotechnology and Pharmaceuticals, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=3WN&utm_medium=003

The Nanoparticles in Biotechnology and Pharmaceuticals market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Nanoparticles in Biotechnology and Pharmaceuticals market.

This study analyzes the growth of Nanoparticles in Biotechnology and Pharmaceuticals based on the present, past and futuristic data and will render complete information about the Nanoparticles in Biotechnology and Pharmaceuticals industry to the market-leading industry players that will guide the direction of the Nanoparticles in Biotechnology and Pharmaceuticals market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Nanoparticles in Biotechnology and Pharmaceuticals market. Additionally, it includes a share of each segment of the Nanoparticles in Biotechnology and Pharmaceuticals market, giving methodical information about types and applications of the market.

Reasons for Buying Nanoparticles in Biotechnology and Pharmaceuticals Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Nanoparticles in Biotechnology and Pharmaceuticals market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=3WN&utm_medium=003

In the end, the Nanoparticles in Biotechnology and Pharmaceuticals market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Nanoparticles in Biotechnology and Pharmaceuticals market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 -...

The 69 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, AKROs 69 overall rating means the stock scores better than 69 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Akero Therapeutics Inc (AKRO) stock is trading at $37.69 as of 11:28 AM on Wednesday, Jul 8, a rise of $0.63, or 1.7% from the previous closing price of $37.06. Volume today is above average. So far 935,742 shares have traded compared to average volume of 380,338 shares. The stock has traded between $37.50 and $41.00 so far today.

To see the top 5 stocks in Biotechnology click here.

See original here:
Is Akero Therapeutics Inc (AKRO) Stock a Good Buy in Biotechnology - InvestorsObserver

The globalwhite biotechnology marketis highly consolidated, as key players are holding 71% share in the global market, reports Transparency Market Research. Prominent players in the market are investing heavily in research and development activities in order to produce effective and better results. These players are also investing in mergers and acquisition, collaboration, partnership, and innovation to get a stronger hold in the market. Apart from key players, few small and medium players are also engaging in these strategies mainly to maintain their position in the market. In this report, researchers have analyzed few leading players including Cargill Inc., Archer Daniels Midland Company, DuPont, BASF SE, and Novozymes.

As per TMRs report, the global white biotechnology market is expected to rise at 4.50% CAGR over the projected tenure between 2016 and 2024. If the market progresses at this rate, the markets revenue is likely to reach US$262.3 bn by the end of 2024. In 2015, the market earned US$ US$178.1 bn.

On the basis of product, the demand in the biofuel segment is high. In 2015, this segment held 31.16% share in the global white biotechnology market. Over the forecast period, this segment is likely to maintain its position. In terms of application, others segment is expected to lead the global market. On the regional front, North America to hold maximum share in the global white biotechnology market. Increasing funding from government for research and development activities in the field of white biotechnology has fueled demand in North America white biotechnology market

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2317

Increasing Government Support to Benefit Growth in White Biotechnology

Rising government initiatives to promote white biotechnology is one of the major factor driving demand in the global white biotechnology market. In addition, white technology is also environment friendly and produces low waste by using efficient methods of production. The white biotechnology cannot be compared with oil and crop prices, as the prices of this technology keep on fluctuating rapidly. Furthermore, growing need from various consumer industries such as consumer goods and automotive to meet sustainability targets is projected to augment technology demand over the projected period.

Adding further to the growth factors, increasing government support to growth of white biotechnology through research and development activities and schemes are also expected to expand growth opportunities for the global white biotechnology market. Moreover, increasing demand for green chemicals in developed regions who are ready to pay higher prices for renewable products will further accelerate demand in this market.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2317

Deteriorating Fertility of Agricultural Lands Might Hamper Growth in White Biotechnology Market

The key challenge that might hamper the growth in the global white biotechnology market includes deteriorating fertility of agricultural lands. This takes place due to over and misuse of fertilizers upon crops that resulted in depleting fertility from agricultural lands. Due to over utilization of fertilizers, the prices of bio-crops have been fluctuated, as there was uncertainty of production yield of bio-crops. Moreover, use of traditional foods and fuels by customers is also expected to hamper growth in the global white biotechnology market.

The study presented here is based on a report by Transparency Market Research (TMR) titled White Biotechnology Market (Product Biochemical, Biofuel, Biomaterial, Bioproduct; Application Food and Feed, Pharmaceuticals, Pulp and Paper, Textile, Energy; Feedstock Grains and Starch Crops, Agricultural Residues, Food Waste, Forestry Material, and Animal) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 2024.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The global white biotechnology market is segmented based on:

Product

Application

Feedstock

Regional

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-reach-us-26-2-bn-in-2027-drug-makers-focus-on-combination-therapies-transparency-market-research-301011476.html

2.https://www.biospace.com/article/peptide-therapeutics-market-to-experience-extensive-growth-thanks-to-rising-demands-for-improved-healthcare/

Read the rest here:
Analysis of Potential Impact of COVID-19 on White Biotechnology Market - Cole of Duty

The Pharmaceutical and Biotechnology Machines Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of pharmaceutical and biotechnology machines market with detailed market segmentation by of product and end user/application. The pharmaceutical and biotechnology machines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pharmaceutical and biotechnology machines market and offers key trends and opportunities in the market.

Some of the key players profiled in the study are Air Liquide, Atlas Copco AB, Beijing Orient, Linde Healthcare, Messer Group, Nanning Lantian, Shenwei Medical, Shenzhen Gaofa, Sicgil India Limited, SOL Group, Taiyo Nippon Sanso, etc.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00011795/

What is Pharmaceutical and Biotechnology Machines Market?

The biotechnology machine is for process Separations. Also, process-scale separation systems, mainly high-volume chromatography systems, are among the most crucial biotechnology machine in the modern biopharmaceutical industry. Its applications of process chromatography include recombinant protein purification. Pharmaceutical biotechnology refers to the use of biotechnology for manufacturing drugs, gene therapy as well as gene testing. This is done by manipulating and modifying organisms, usually at the molecular level.

The pharmaceutical and biotechnology machines market is propelling due to advancement of technology and rising geriatric population. However, the high cost of devices, stringent regulations, and lack of skilled personnel hamper the market growth.

The pharmaceutical and biotechnology machines market is segmented on the basis of product and end user/application. Based on product, the market is segmented as oxygen, nitrous oxide, medical air and others(nitrogen, carbon dioxide and helium). On the basis of end user/application, the market is categorized as hospitals (labs and clinics), home healthcare, universities/research institutions and pharmaceutical and biotechnology industries.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price @ https://www.theinsightpartners.com/discount/TIPRE00011795/

Key questions answered by this report:

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011795/

Pharmaceutical and Biotechnology Machines Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Read the original:
Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? - Apsters News

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on development of first-in-class drugs, announced today that encouraging preclinical results supporting newly-identified immunogenic effects of the companys lead product candidate, investigational THIO (6-thio-dG), the only telomere-by-telomerase targeting agent in development for the treatment of cancer, has been published in Cancer Cell, a renowned peer-reviewed scientific journal covering major advances in cancer research. The manuscript entitled: Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Mender et al., is now featured online and will also be published in the September 2020 edition of Cancer Cell, Volume 38, pages 1-12.

Telomerase is the enzyme responsible for the maintenance of telomeres. While inactive in most normal cells, telomerase is activated in the majority of cancer cells, making it an attractive target for cancer therapy. Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage. The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy. THIOs activity was shown to be cancer-specific in tumor types with active telomerase. Since up to 35 million patients have telomerase-positive cancers, MAIA Biotech believes these results suggest that THIO holds significant potential to treat large patient populations across many types of cancers.

In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses. THIO was shown to be directly incorporated into telomeres by telomerase, where it rapidly induced telomeric DNA damage responses, which is selective to telomerase-positive TERT(+) cancer cells without affecting normal telomerase-silent cells. The findings also indicated that THIO induces DNA-mediated innate sensing and activation of immune responses in a host cGAS/STING-dependent manner, leading to improved anti-tumor efficacy. Low doses of THIO, followed by anti-PD-L1 therapy, completely eliminated advanced tumors in preclinical models and produced cancer cell specific immune memory where the immune system continued to be active against the cancer cells after extended periods of time with no additional treatment. These results are significant as they demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining telomere-targeted therapy with immunotherapy.

We believe THIO has the potential to transform the immuno-oncology landscape and change the cancer treatment paradigm, and these most recent findings provide a strong rationale for combining telomere-targeted therapy with immunotherapy, stated Vlad Vitoc, MD, MAIAs Chief Executive Officer and President. We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program. We are highly encouraged by these promising findings of tumor elimination, cancer specific immune responses, and stimulation of immune memory, which build upon prior positive preclinical results. These findings provide further support for the companys plans to advance THIO into Phase 1 clinical studies in 2021.

About THIO

THIO (6-thio-dG) is a small molecule in preclinical development and is the only telomere-by-telomerase targeting agent currently in development. THIO is designed to selectively kill cancer cells by modifying telomeric DNA structure and function utilizing telomerase. Telomerase is present in >85% of human cancers and contributes significantly to proliferation and immortality of cancer cells. THIO is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, it compromises the telomere structure and function, leading to uncapping of the chromosome ends and thus resulting in rapid tumor cell death. In preclinical studies, this rapid cancer cell death occurred without impacting normal cells. THIO is investigational and has not been approved for any use anywhere in the world.

About Cancer Cell

Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering manuscripts is whether the studies provide major advances into answering important questions relevant to naturally occurring cancers. Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of-principle clinical studies. For more information, please visit http://www.cell.com/cancer-cell or follow the journal on Twitter: @Cancer_Cell.

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. MAIAs business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure. Drug candidates include (i) THIO, a telomere-by-telomerase targeting agent in preclinical development for the treatment of telomerase positive cancer cells; (ii) GMC1, a FKBP52 co-chaperone-inhibitor being evaluated for prostate cancer and breast cancer; and (iii) MJC13 is a drug candidate with a potentially novel mode of action targeting androgen receptor (AR) inhibition that is important in prostate and breast cancers. MAIA is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into clinical trials. For more information, please visit http://www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industrys actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as may, might, will, should, could, expect, plan, anticipate, believe, estimate, project, intend, future, potential or continue, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005271/en/

Read more here:
MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO -...

There is an unexpected shift in the world, and many sectors are experiencing thoughts triggered by the COVID-19 pandemic. The outbreak of COVID-19 has had a positive impact on the demand for chromatography. In the pharmaceutical industry, chromatography technology is commonly used for the detection of cancer cells. It is also used for drinking water and air processing, plasma fractionation, enzyme purification, and purification. The Environmental Authority, for example, listed chromatography as safe for the measurement of drinking water purity as a means of easy propagation of the coronavirus through polluted water. During this coronavirus crisis, we are helping our clients in understanding the impact of COVID-19 on the chromatography system market.

Our report includes:

A new report by Research Dive states that the global chromatography system market is set to grow at a CAGR of 6.9% and is projected to garner a revenue of $16,304.0 million during the period of forecast from 2019 to 2026. The report delivers in-depth insights into opportunities, vital segments, restraints, drivers, and prominent players of the global market. Based on the type, end-use, and region of the global market segmentation. The report offers insights on drivers, opportunities, restraints, analysis of segment, and competitive market players. Increasing the use of chromatography methods in the pharmaceutical industry is a significant factor for market growth, according to our analysts. Nonetheless, due to the existence of capillaries for the oxygen, hydrogen, and methane separation, a requirement of qualified professionals and high construction costs and maintenance costs is anticipated to impede the growth of the market for the chromatography device. The global market is segmented on the basis of type, end-use industry, and region.

Check out How COVID-19 impact on the Chromatography Systems Market. Click here to Connect with Analyst @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market#myQueryForm

Pharmaceutical and biotechnology Segment to be the Most Lucrative

The chromatography device market is categorized on the basis of end-use application into hospitals and medical, pharmaceutical, and biotechnology industries and the food and agriculture industry. The demand for pharmaceuticals and biotechnology is projected to rise by 7.3% CAGR, with $5,651.4 million anticipated by 2026. The need for highly sensitive product information in terms of quality and purity, increased use of biopharmaceuticals, especially bio-similar medicines, and monoclonal antibodies that are expected to drive the need for chromatography system are all contributing to the size of the market in the prediction time frame.

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026 @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market

Asia-Pacific Region to Expand Business at a Considerable Growth Rate

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026. The rise in research activities in different fields, such asbiological innovation and pharmaceutical purpose, has contributed to this dominance. A substantial increase is expected to result in sales of $3,283.9 million by 2026, with a 7.5% CAGR in demand for Asia-Pacific RO water treatment system components. In Asia-Pacific, this anticipated rise is mainly due to the existence, of several biopharmaceutical research and development centres, in various major companies such as Merck, Eli Lilly, and Pfizers. These factors are anticipated to fuel the growth of the market over time.

Prominent Players of the Market

Some of the key players of the global chromatography system market include Agilent Technologies (NYSE: A), Perkin Elmer, APIX, Thermo Fisher Scientific Inc., Xylem (OI Analytical), CDS Analytical, Shimadzu Corporation, Waters Corporation, Jasco Inc, Bio-Rad Laboratories and others. These players are adopting several strategies such as mergers & acquisitions and novel product developments to improve their company position in the global industry.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

Read more:
Pharmaceutical and biotechnology Segment to be the Most Lucrative in Chromatography Systems Market - Jewish Life News

A rating of 80 puts Immunomedics, Inc. (IMMU) near the top of the Biotechnology industry according to InvestorsObserver. Immunomedics, Inc.'s score of 80 means it scores higher than 80% of stocks in the industry. Immunomedics, Inc. also received an overall rating of 70, putting it above 70% of all stocks. Biotechnology is ranked 13 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Immunomedics, Inc. (IMMU) stock is trading at $41.15 as of 1:12 PM on Monday, Jul 6, an increase of $3.61, or 9.62% from the previous closing price of $37.54. The stock has traded between $39.22 and $41.40 so far today. Volume today is 3,753,250 compared to average volume of 3,897,633.

To see the top 5 stocks in Biotechnology click here.

Follow this link:
Is Immunomedics, Inc. (IMMU) a Winner in the Biotechnology Industry? - InvestorsObserver

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 1.74% from its latest closing price when compared to the 1-year high value of $75.00 and move down -82.84%, while VIR stocks collected +5.64% of gains with the last five trading sessions. Press Release reported 17 hours ago that Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) 2 of the analysts out of 5 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $32.50 which is -$6.35 below current price. VIR currently has a short float of 2.80% and public float of 99.67M with average trading volume of 1.65M shares.

VIR stocks went up by 5.64% for the week, with the monthly jump of 20.61% and a quarterly performance of 41.45%. The simple moving average for the period of the last 20 days is 7.60% for VIR stocks with the simple moving average of 62.80% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -45.31% of loss for the given period.

The stock volatility was left at 9.77%, however, within the period of a single month, the volatility rate increased by 9.02%, while the shares surge at the distance of +23.52% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +31.69% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +5.64%, in comparison to the 20-day moving average settled at $38.51. In addition, Vir Biotechnology, Inc. saw 226.20% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Horn Howard, who sold 10,000 shares at the price of $40.00 back on Jul 02. After this action, Rushing now owns 207,777 shares of Vir Biotechnology, Inc., valued at $400,000 with the latest closing price.

Parrish Jay, the Chief Business Officer of Vir Biotechnology, Inc., sold 75,000 shares at the value of $37.95 during a trade that took place back on Jul 01, which means that Parrish Jay is holding 222,222 shares at the value of $2,846,310 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read the rest here:
Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations - The News Heater